Grail, Inc. (GRAL)
First-Class Amenity Kits Have Become Holy Grail Collectibles
For a rare breed of travel enthusiast, the free toiletry pouches are more than a throwaway convenience. They're a trip down memory lane.
Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.
Grail's stock surged after a positive FDA panel vote. Insurer adoption is crucial for Galleri's success.
Grail's Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval
The FDA is expected to make its final ruling on Galleri's premarket approval in the coming months.
GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting
GRAIL NASDAQ: GRAL Chief Financial Officer Aaron Freidin said the company's Galleri multi-cancer early detection test recorded strong first-half growth as it expanded distribution through digital health platforms, employers and physician offices.
GRAIL: Looking Beyond The NHS-Galleri Headline
GRAIL faces a binary FDA approval event for Galleri, with significant stock movement expected based on the outcome. Despite disappointing NHS-Galleri trial results, I believe the true value of the test would have been apparent with a longer monitoring period. While GRAL has a solid cash position, commercialization delays could see the company having to raise a large amount of capital on unfavorable terms.
US FDA to hold advisory meeting to review Grail's multi-cancer test
Grail said on Friday the U.S. FDA plans to hold a meeting of outside experts to review its multi-cancer screening test Galleri in September, sending its shares up 4% in morning trade.
GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcript
GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcript
GRAIL Q2 Earnings Call Highlights
GRAIL NASDAQ: GRAL reported second-quarter revenue growth driven by higher Galleri test volumes, while outlining continued efforts to secure FDA approval, expand its commercial organization and build international distribution partnerships.
GRAIL, Inc. (GRAL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
GRAIL, Inc. (GRAL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
GRAIL, Inc. (GRAL) Shareholder/Analyst Call Transcript
GRAIL, Inc. (GRAL) Shareholder/Analyst Call Transcript
GRAIL's Galleri Test Cuts Stage 4 Cancer Diagnoses in Study Despite Missed Endpoint
GRAIL NASDAQ: GRAL said new data presented at the American Society of Clinical Oncology annual meeting showed its Galleri multi-cancer early detection blood test can identify more cancers through screening and reduce stage 4 diagnoses, though the company confirmed that a primary endpoint in its largest randomized trial was not met.
GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move Ahead
GRAIL NASDAQ: GRAL said demand for its Galleri multi-cancer early detection test has continued to grow despite recent headlines related to its NHS study, according to comments made by Aaron, who identified himself during the discussion as the company's CFO, at a Bank of America event.
